YS Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
YS Biopharma has a total shareholder equity of CN¥474.5M and total debt of CN¥548.9M, which brings its debt-to-equity ratio to 115.7%. Its total assets and total liabilities are CN¥1.5B and CN¥1.0B respectively.
Key information
115.7%
Debt to equity ratio
CN¥548.95m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥222.61m |
| Equity | CN¥474.51m |
| Total liabilities | CN¥1.04b |
| Total assets | CN¥1.51b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YS's short term assets (CN¥826.6M) do not cover its short term liabilities (CN¥882.9M).
Long Term Liabilities: YS's short term assets (CN¥826.6M) exceed its long term liabilities (CN¥153.1M).
Debt to Equity History and Analysis
Debt Level: YS's net debt to equity ratio (68.8%) is considered high.
Reducing Debt: Insufficient data to determine if YS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YS has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: YS is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.